GLADYS DOLOR: Open Payments
NPI 1285207043 · CARSON CITY, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,140 in 160 payments from 45 companies in 2025. Trend: 2023 $2,351 · 2024 $2,591 · 2025 $4,140
Food & beverage: $3,853Education: $287
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $531 |
| Janssen Biotech, Inc. | 12 | $379 |
| E.R. Squibb & Sons, L.L.C. | 15 | $365 |
| Astellas Pharma US Inc | 14 | $261 |
| Merck Sharp & Dohme LLC | 7 | $199 |
| ABBVIE INC. | 11 | $176 |
| Daiichi Sankyo Inc. | 11 | $159 |
| Novartis Pharmaceuticals Corporation | 8 | $158 |
| Exelixis Inc. | 3 | $131 |
| PFIZER INC. | 6 | $126 |
Products named: Enhertu, RYBREVANT, KEYTRUDA, OPDIVO, IMFINZI, ERLEADA, CABOMETYX, Padcev.
Industry payments across NV — which companies pay providers there.
